Pfizer (PFE.N) said its experimental eczema drug tilrekimig met the main goal in a mid-stage trial, sending shares up marginally as the drugmaker plans late-stage testing this year.
The positive Phase 2 results position Pfizer to compete in the lucrative atopic dermatitis market, where established treatments like Regeneron’s Dupixent generated over $10 billion in annual sales.
Key Takeaways
- Tilrekimig showed significant symptom reduction after 16 weeks
- Phase 3 trial expected to begin this year
- Drug targets $15 billion eczema treatment market
Trial Results Show Promise
Patients treated with tilrekimig experienced significant reduction in eczema symptoms after 16 weeks compared to placebo, Pfizer said Monday1. Across three different doses tested, between 38.7% and 51.9% of patients showed strong improvement, all rates higher than placebo.
The drug demonstrated a favorable safety profile with good tolerability throughout the study period. Pfizer is testing tilrekimig in patients with moderate to severe atopic dermatitis, a chronic skin condition causing widespread rashes, itching, and inflammation that disrupts daily activities.
Market Competition Intensifies
The eczema treatment landscape includes several billion-dollar drugs, with Regeneron (REGN.O) and Sanofi’s (SASY.PA) Dupixent leading at over $10 billion in annual revenue1. Other competitors include AbbVie’s (ABBV.N) Rinvoq and Eli Lilly’s (LLY.N) recently approved Ebglyss.
Pfizer’s entry could capture meaningful market share in the estimated $15 billion global atopic dermatitis market. The company plans to also develop tilrekimig for asthma and chronic obstructive pulmonary disease, potentially expanding its commercial opportunity.
Broader Development Strategy
The successful mid-stage results represent a key milestone for Pfizer’s dermatology pipeline following recent setbacks in other therapeutic areas. The company has been working to rebuild investor confidence after several high-profile drug failures and patent cliff pressures on key products.
Phase 3 trials typically involve larger patient populations and longer study periods to confirm efficacy and safety before potential regulatory approval. If successful, tilrekimig could launch by 2028, analysts estimate.
Investment Implications
While the trial success provides validation for Pfizer’s research capabilities, investors remain cautious given the competitive eczema market and the company’s recent execution challenges. The stock showed limited reaction to the news, reflecting market skepticism about late-stage development risks.
Success in Phase 3 trials could generate several billion dollars in peak annual sales, providing much-needed growth for Pfizer’s post-pandemic portfolio transition.
Not investment advice. For informational purposes only.
References
1Reuters (March 9, 2026). “Pfizer’s eczema drug meets main goal in mid-stage trial, plans late-stage study”. Reuters. Retrieved March 9, 2026.
2Yahoo Finance (March 9, 2026). “Pfizer’s eczema drug meets main goal in mid-stage trial, plans late stage study”. Yahoo Finance. Retrieved March 9, 2026.
3MarketScreener (March 9, 2026). “Pfizer’s eczema drug meets main goal in mid-stage trial, plans late-stage study”. MarketScreener. Retrieved March 9, 2026.
4Express Pharma (May 16, 2019). “Pfizer’s atopic dermatitis treatment meets goals in late-stage study”. Express Pharma. Retrieved March 9, 2026.